评中国成人2型糖尿病胰岛素促泌剂应用专家共识  

Evaluation of the Expert Consensus on Insulin Secretagogues Application in Chinese Adults with Type 2 Diabetes

作　　者：黄李[1] 童南伟[1] 

机构地区：[1]四川大学华西医院内分泌代谢科,成都610041

出　　处：《临床药物治疗杂志》2013年第1期42-44,共3页Clinical Medication Journal

摘　　要：中国成人2型糖尿病的病理生理特点与欧美国家不同,其β细胞胰岛素分泌功能下降可能比胰岛素敏感性降低更明显。因此,中国成人2型糖尿病患者适合使用胰岛素促泌剂。为了强调其重要性,2012年4月在《中华内分泌代谢杂志》发表了《中国成人2型糖尿病胰岛素促泌剂应用的专家共识》,它对我国临床实践具有重要指导意义。本文重点评价了目前对胰岛素促泌剂认识的一些误区,比如低血糖、体重、β细胞功能及心血管安全性等问题。The pathophysiologic characteristics of Chinese adults with type 2 diabetes（T2D） are different from those of patients from the European and American,reduction of insulin secretion function may be more severe compared to the decrease of insulin sensitivity.Therefore,insulin secretagogues are suitable for Chinese T2D.The expert consensus on insulin secretagogues application in Chinese adults with type 2 diabetes was published on Chinese Journal of Endocrinology and Metabolism in April 2012 and it is an important guidline for clinical practice in China.This paper focuses on evaluating some misunderstandings in the current knowledge of insulin secretagogues,such as hypoglycemia,weight,β cell function and cardiovascular safety etc.

关 键 词：胰岛素促泌剂 2型糖尿病 磺脲类药物 

分 类 号：R977.15[医药卫生—药品] R587.1[医药卫生—药学]